Table 2.

Treatment efficacy and survival condition for the combined treatment group

Variables, n (%)	Apatinib combined with chemotherapy group	Apatinib + ICI with chemotherapy group	P‐value
	(N = 19)	(N = 25)
CR	0 (0%)	0 (0%)	0.398
PR	12 (63.1%)	17 (68.0%)
SD	5 (26.3%)	3 (12.0%)
PD	2 (10.5%)	5 (20.0%)
ORR	12 (63.1%)	17 (68.0%)	0.759
DCR	17 (89.4%)	20 (80.0%)	0.680

ICI, immune checkpoint inhibitors, CR complete response, PR partial response, SD stable disease, PD progressive disease, ORR objective response rate, DCR disease control rate